A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 60,894 shares of EDIT stock, worth $75,508. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,894
Previous 65,097 6.46%
Holding current value
$75,508
Previous $304,000 31.91%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$3.39 - $5.96 $14,248 - $25,049
-4,203 Reduced 6.46%
60,894 $207,000
Q2 2024

Jul 19, 2024

BUY
$4.67 - $7.28 $5,688 - $8,867
1,218 Added 1.91%
65,097 $304,000
Q1 2024

Apr 22, 2024

BUY
$7.03 - $11.07 $26,074 - $41,058
3,709 Added 6.16%
63,879 $473,000
Q4 2023

Jan 16, 2024

BUY
$6.25 - $11.11 $84,837 - $150,807
13,574 Added 29.13%
60,170 $609,000
Q3 2023

Oct 24, 2023

SELL
$6.92 - $9.31 $8,089 - $10,883
-1,169 Reduced 2.45%
46,596 $363,000
Q2 2023

Jul 25, 2023

BUY
$6.36 - $11.47 $15,136 - $27,298
2,380 Added 5.24%
47,765 $393,000
Q1 2023

Apr 14, 2023

BUY
$7.03 - $11.53 $35,374 - $58,018
5,032 Added 12.47%
45,385 $329,000
Q4 2022

Feb 08, 2023

BUY
$8.32 - $13.21 $499 - $792
60 Added 0.15%
40,353 $357,000
Q3 2022

Oct 25, 2022

BUY
$12.16 - $19.42 $39,702 - $63,406
3,265 Added 8.82%
40,293 $493,000
Q2 2022

Aug 12, 2022

BUY
$9.99 - $21.35 $619 - $1,323
62 Added 0.17%
37,028 $438,000
Q1 2022

May 11, 2022

SELL
$14.08 - $27.63 $49,181 - $96,511
-3,493 Reduced 8.63%
36,966 $703,000
Q4 2021

Feb 08, 2022

SELL
$26.55 - $40.57 $330,627 - $505,218
-12,453 Reduced 23.54%
40,459 $1.07 Million
Q3 2021

Nov 02, 2021

BUY
$39.27 - $72.94 $175,536 - $326,041
4,470 Added 9.23%
52,912 $2.17 Million
Q2 2021

Aug 11, 2021

BUY
$31.29 - $56.64 $13,892 - $25,148
444 Added 0.93%
48,442 $2.74 Million
Q1 2021

May 14, 2021

SELL
$39.71 - $90.58 $506,302 - $1.15 Million
-12,750 Reduced 20.99%
47,998 $2.02 Million
Q4 2020

Feb 12, 2021

BUY
$27.07 - $84.35 $341,704 - $1.06 Million
12,623 Added 26.23%
60,748 $4.26 Million
Q3 2020

Nov 04, 2020

BUY
$28.06 - $37.16 $42,033 - $55,665
1,498 Added 3.21%
48,125 $1.35 Million
Q2 2020

Jul 17, 2020

BUY
$18.5 - $34.34 $318,644 - $591,472
17,224 Added 58.58%
46,627 $1.38 Million
Q1 2020

Apr 21, 2020

BUY
$14.88 - $32.78 $97,910 - $215,692
6,580 Added 28.83%
29,403 $583,000
Q4 2019

Feb 12, 2020

BUY
$19.49 - $32.63 $89,692 - $150,163
4,602 Added 25.26%
22,823 $676,000
Q3 2019

Nov 07, 2019

SELL
$22.49 - $26.81 $9,108 - $10,858
-405 Reduced 2.17%
18,221 $414,000
Q2 2019

Aug 06, 2019

SELL
$20.48 - $27.76 $88,186 - $119,534
-4,306 Reduced 18.78%
18,626 $461,000
Q1 2019

May 06, 2019

BUY
$19.43 - $26.41 $13,484 - $18,328
694 Added 3.12%
22,932 $561,000
Q4 2018

Feb 11, 2019

SELL
$18.19 - $31.79 $120,035 - $209,782
-6,599 Reduced 22.88%
22,238 $506,000
Q3 2018

Nov 14, 2018

BUY
$27.65 - $38.39 $187,218 - $259,938
6,771 Added 30.69%
28,837 $918,000
Q2 2018

Jul 30, 2018

BUY
$31.4 - $41.01 $331,458 - $432,901
10,556 Added 91.71%
22,066 $791,000
Q1 2018

Apr 16, 2018

BUY
$29.84 - $44.08 $46,281 - $68,368
1,551 Added 15.57%
11,510 $382,000
Q4 2017

Feb 09, 2018

BUY
$21.89 - $31.34 $218,002 - $312,115
9,959
9,959 $306,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $85.2M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.